Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
VTAK vs ERNA: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
VTAK Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 4–2 Matrix Metrics)
VTAK Overall Winner
6-Pillar Tally: VTAK 2 – 2 ERNA (2 Tie)
Matrix Metrics: VTAK 4 – 2 ERNA
As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Ernexa Therapeutics Inc. (ERNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas ERNA carries 45.6/100 (HOLD) at $1.69 (N/M Forward P/E, 0.0% operating margin).
- Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile ERNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About VTAK vs ERNA
VTAK
Head-to-Head Winner
Catheter Precision, Inc.
$0.15
-0.66% 1D
Market Cap
$548,639
TTM Revenue
$1.9M
Forward P/E
N/M
Beta / 30D Vol
0.19β · 76% Vol
Unified Composite Score
58.1
HOLD
Tech 72.0
Fund 70.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
ERNA
Ernexa Therapeutics Inc. Common Stock
$1.69
+0.6% 1D
Market Cap
$2.8M
TTM Revenue
$1,000
Forward P/E
N/M
Beta / 30D Vol
-5.48β · 90% Vol
Unified Composite Score
45.6
HOLD
Tech 36.0
Fund 50.0
Flow 50.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (VTAK 2 – 2 ERNA)
1. Valuation Multiples
VTAK
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
0.3x
N/M
2. Growth & Scale
VTAK
Revenue Growth (YoY)
+380.7%
-94.1%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$1.9M
$1,000
Market Cap
$548,639
$2.8M
3. Profitability & Quality
ERNA
Gross Margin
47.7%
100.0%
Operating Margin
-388.1%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-111.3%
-320.7%
4. Balance Sheet & Cash Flow
ERNA
Cash Generation (TTM)
-$10M EBITDA
-$12M EBITDA
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.87 Book/Sh · -111.3% ROE
$8.8M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
Tie
Options Structure Phase
UNCLASSIFIED
UNCLASSIFIED
Current IV / %ile
N/A (N/A)
N/A (N/A)
Put/Call OI Skew
N/A
N/A
OBV Trend / Tech Phase
NEUTRAL · Markdown
NEUTRAL · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Medical Devices Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: VTAK (4) vs ERNA (2)| Institutional Metric | VTAK | ERNA | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $548,639 | $2.8M | Tie | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +380.7% | -94.1% | VTAK | |
| Operating Margin (TTM) | -388.1% | 0.0% | ERNA | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -111.3% | -320.7% | VTAK | |
| 52-Week Range Position | 1% ($0–$3) | 10% ($0–$16) | ERNA | |
| Beta / 30D Volatility | 0.19β · 76% Vol | -5.48β · 90% Vol | VTAK | |
| Unified Institutional Score | 58.1 / 100 (HOLD) | 45.6 / 100 (HOLD) | VTAK | |
| Trailing 12M Revenue (USD) | $1.9M | $1,000 | Scale | |
| Gross Profit Margin (TTM) | 47.7% | 100.0% | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 0.3x EV/Rev | N/M PEG · N/M EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$10M EBITDA ($4.87 Book/Sh · -111.3% ROE) | -$12M EBITDA ($8.8M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
VTAK +10.04 pp
3M Horizon
ERNA +26.25 pp
6M Horizon
ERNA +1460.07 pp
1Y Horizon
ERNA +181.17 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VTAK Revenue | ERNA Revenue | VTAK Op. Margin | ERNA Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $10M | $20M | -498.0% | 0.9% | ERNA |
| FY2019 | $10M | $20M | -801.9% | -8.9% | ERNA |
| FY2020 | $0M | $10M | -13668.3% | -125.0% | ERNA |
| FY2021 | $0M | N/A | -133027.3% | N/A | VTAK |
| FY2022 | $0M | N/A | -192578.6% | N/A | VTAK |
| FY2023 | $0M | $0M | -17674.0% | -31080.9% | VTAK |
| FY2024 | $0M | $0M | -2676.9% | -2693.1% | VTAK |
| FY2025 | $0M | N/A | -2581.6% | N/A | VTAK |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
VTAK
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact VTAK Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ERNA
UNCLASSIFIED
Current IV
N/A
IV Percentile
N/A
Put/Call OI Skew
N/A
IV Regime
Unclassified
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
NEUTRAL
OBV Flow
NEUTRAL
Exact ERNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
VTAK Moat Profile
Cyclical / Execution-Driven Positioning
Medical Devices Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ERNA Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ VTAK vs ERNA Key Questions & Quantitative Answers
As of Nov 16, 2026, Catheter Precision, Inc. (VTAK) is the stronger overall head-to-head candidate over Ernexa Therapeutics Inc. (ERNA) in the Tradestie Institutional Equity Comparison Engine, winning 4–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale). VTAK carries a Unified Composite Score of 58.1/100 (HOLD) at $0.15 (N/M Forward P/E, -388.1% operating margin), whereas ERNA carries 45.6/100 (HOLD) at $1.69 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: VTAK is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.2); meanwhile ERNA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VTAK leads the Growth & Scale pillar: VTAK posts +380.7% YoY revenue growth and +0.0% YoY earnings growth on $1.9M TTM revenue (47.7% gross margin, -388.1% operating margin), compared with ERNA at -94.1% YoY revenue growth and +0.0% YoY earnings growth on $1,000 TTM revenue (100.0% gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), VTAK cumulative revenue shifted +0.0% while ERNA shifted -50.0%. In operating R&D and SG&A reinvestment, VTAK deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ERNA.
VTAK screens cheaper on headline valuation multiples. VTAK trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.3x EV/Revenue (unreported EBITDA margin), whereas ERNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VTAK (-111.3% ROE) versus ERNA (-320.7% ROE) capital efficiency.
In options market volatility and institutional positioning, VTAK carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.19β · 76% Vol realized risk). By comparison, ERNA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.48β · 90% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ERNA vs VTAK · Reverse Pair
VTAK vs EPOW
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem
LLY vs NVO
· GLP-1 Biopharma
AVGO vs MRVL
· Custom ASIC & Networking
VRT vs ETN
· AI Power & Thermal